HMBD-001

Other Medications

Not submitted to EMA

Not available 2 Clinical Trials

Description

HMBD-001 is an experimental drug currently being studied in clinical trials for certain advanced solid tumors, including those with high levels of the HER3 protein or specific gene changes (like NRG1 fusions). It is a monoclonal antibody, meaning it's designed to target a specific protein involved in cancer growth. The trials are designed to determine the safest dose of HMBD-001, understand its side effects, and see if it can shrink tumors or slow their growth, both when given alone and in combination with other cancer drugs like enzalutamide. While not yet approved for colorectal cancer, the trials are investigating its potential in cancers expressing HER3 or having NRG1 fusions, which might include some colorectal cancers. The trials are in early phases, focusing on safety and initial effectiveness.

Mechanism of Action

HMBD-001 is a monoclonal antibody designed to target the HER3 protein. HER3 is found on the surface of some cancer cells and plays a role in their growth and survival. By binding to HER3, HMBD-001 aims to interfere with the signals that promote cancer cell growth, potentially leading to their death or slowing their proliferation. The specific mechanism by which HMBD-001 affects HER3 signaling is being further investigated in clinical trials.

Side Effects

HMBD-001 is an investigational drug And its side effects are still being evaluated in ongoing clinical trials. The trials are designed to carefully monitor participants for any adverse events. Common side effects associated with monoclonal antibodies can include infusion-related reactions (like fever Chills Nausea) Fatigue And other effects depending on the specific drug and its target. More specific side effect information will become available as the trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05919537 Phase 1

Active, not recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Australia

NCT05057013 Phase 1

Active, not recruiting

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

United Kingdom

Quick Info

Category	Other Medications
EMA Status	Not submitted to EMA
Spain Access	Not available
Clinical Trials	2

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.